Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis.

Giacomelli, Roberto and Afeltra, Antonella and Alunno, Alessia and Bartoloni-Bocci, Elena and Berardicurti, Onorina and Bombardieri, Michele and Bortoluzzi, Alessandra and Caporali, Roberto and Caso, Francesco and Cervera, Ricard and Chimenti, Maria Sole and Cipriani, Paola and Coloma, Emmanuel and Conti, Fabrizio and D'Angelo, Salvatore and De Vita, Salvatore and Di Bartolomeo, Salvatore and Distler, Oliver and Doria, Andrea and Feist, Eugen and Fisher, Benjamin A and Gerosa, Maria and Gilio, Michele and Guggino, Giuliana and Liakouli, Vasiliki and Margiotta, Domenico Paolo Emanuele and Meroni, Pierluigi and Moroncini, Gianluca and Perosa, Federico and Prete, Marcella and Priori, Roberta and Rebuffi, Chiara and Ruscitti, Piero and Scarpa, Raffaele and Shoenfeld, Yehuda and Todoerti, Monica and Ursini, Francesco and Valesini, Guido and Vettori, Serena and Vitali, Claudio and Tzioufas, Athanasios G (2019) Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity reviews, 18 (1). pp. 93-106. ISSN 1873-0183.

Full text not available from this repository.
Official URL: https://www.sciencedirect.com/science/article/pii/...

Abstract

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

Item Type: Article
Subjects: WD Diseases and disorders of systemic, metabolic or environmental origin > WD350 Immunologic diseases
WD Diseases and disorders of systemic, metabolic or environmental origin > WD811 Rheumatology
WL Nervous system. Neurology
Divisions: Ambulatory Care > Rheumatology
Emergency Services > Neurology
Related URLs:
Depositing User: Beth Connors
Date Deposited: 20 Feb 2019 15:46
Last Modified: 20 Feb 2019 15:46
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1842

Actions (login required)

View Item View Item